Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This study has been completed.
Information provided by:
Telik Identifier:
First received: February 12, 2004
Last updated: July 21, 2011
Last verified: June 2005
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: TLK286, cisplatin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Telik:

Primary Outcome Measures:
  • Primary Objectives of the Study [ Time Frame: Every 3 weeks ]
    1. To determine the safety of TLK286 in combination with cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    2. To determine the MTD of TLK286 in combination with cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Estimated Enrollment: 50
Study Start Date: February 2004
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: TLK286, cisplatin
    TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Histologically confirmed non-small cell lung cancer
  • Stage IV or IIIB
  • Measurable disease by RECIST
  • ECOG performance status of 0-1
  • Adequate liver and renal function
  • Adequate bone marrow reserve

Exclusion Criteria:

  • History of bone marrow transplantation or stem cell support
  • Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00077883

United States, Maryland
Univ. of MD, Greenbaum Cancer Center
Baltimore, Maryland, United States, 21201
United States, Tennessee
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
United States, Texas
Univ. of TX, MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
  More Information

Responsible Party: Gail Brown, MD Chief Medical Officer, Telik, Inc. Identifier: NCT00077883     History of Changes
Other Study ID Numbers: TLK286.2021
Study First Received: February 12, 2004
Last Updated: July 21, 2011

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents processed this record on April 28, 2017